BioSpace News Archive

Business

Drugging the Undruggable: How AI Does the (Almost) Impossible

Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.

June 23, 2020
·
4 min read
·
Gail Dutton
Business

Lincoln Equities and HIG Realty Buy 1.2 Million-Square-Foot Life Sciences Campus

“Given the current public health crisis, we anticipate pharmaceutical and life sciences manufacturers to consider ‘reshoring’ and expanding operations in the U.S.,” said Joel Bergstein, president of LEG.

June 23, 2020
·
2 min read
·
Mark Terry
Drug Development

Myovant’s Relugolix Combo Hits the Mark in Endometriosis, Heads to FDA for Prostate Cancer

Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.

June 23, 2020
·
3 min read
·
Mark Terry
Deals

Gilead Continues Expansion into Oncology with Possible $1.75 Billion Deal with Pionyr

Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.

June 23, 2020
·
3 min read
·
Mark Terry
Drug Development

Biopharma Update on the Novel Coronavirus: June 24

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.

June 23, 2020
·
4 min read
·
BioSpace Editorial Staff
CARB-X funds University of Queensland to accelerate the development of a new class of last-resort antibiotics to treat deadly superbug infections

University’s Octapeptin engineered peptides aim to replace last-resort polymyxin antibiotics with a new antibiotic that has no damaging toxic side effects

June 23, 2020
·
8 min read
BioForest

Sana Biotechnology Snags $700 Million in Initial Financing Round

Sana Biotechnology raised $700 million in initial financing that will be used to advance the company’s discovery and development programs that create and deliver engineered cells as a treatment for different disease types.

June 23, 2020
·
2 min read
·
Alex Keown
Business

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC

The diagnostic tool will use Thermo Fisher’s next-generation sequencing (NGS)-based Oncomine Dx Target Test to identify HER2 (human epidermal growth factor receptor 2) gene mutations.

June 23, 2020
·
2 min read
·
Alex Keown
BioMidwest

Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

Esperion announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe.

June 23, 2020
·
5 min read
Business

Sanofi Goes Big on $2 Billion-Plus Vaccine Partnership with Translate Bio

Sanofi Pasteur and Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases. The original deal was entered in 2018.

June 23, 2020
·
4 min read
·
Mark Terry